This Is Why with Dr. Busti

In this episode on This Is Why, Dr. Busti breaks down one of the most commonly misunderstood biostatistics concepts: correlation vs coefficient of determination. You’ll learn how to interpret the correlation coefficient (r), what it actually tells you about relationships between variables, and why it does NOT imply causation.Then we connect that foundation to R² (coefficient of determination) — and This Is Why it’s critical for understanding how much variability one variable explains in another. Through clinical context and practical examples, you’ll see how these concepts apply to real-world decision-making, not just test questions.If you’ve ever confused association with causation or struggled to interpret R values, this episode will help you connect the “why” behind the numbers.Topics Covered:- Correlation coefficient (r) definition- Strength vs direction of relationships- Why correlation does NOT equal causation- Confounding variables explained- Interpreting R values clinically- Coefficient of determination (R²)- Variability explained between variables- Clinical example: calories and weight- Relationship vs prediction in statisticsThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/correlation-coefficient-vs-r-squared👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#correlation coefficient #R squared #biostatistics explained #coefficient of determination #Dr BustiSpeaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

ACE inhibitors after myocardial infarction — Dr. Busti explains the GISSI-3 trial and what it actually changed in clinical practice on this episode of This Is Why.After the initial management of acute MI, the real question becomes: what else improves survival and prevents long-term damage? The GISSI-3 trial tackled this directly, evaluating early ACE inhibitor therapy and routine nitrate use in a large, real-world population.Dr. Busti breaks down how lisinopril provided a modest but meaningful mortality benefit—and why that matters more than it seems. More importantly, we explore the why behind early RAAS blockade, how it impacts ventricular remodeling, and which patients benefit the most.This is not about memorizing treatment steps—it’s about understanding how small, evidence-based decisions compound to improve patient outcomes.Topics Covered:- Why the GISSI-3 trial was needed- Trial design and 2x2 factorial structure- Early ACE inhibitor therapy after MI- Mortality and combined endpoint outcomes- Absolute vs relative risk reduction- Why nitrates did not improve survival- Mechanism of RAAS blockade and remodeling- High-risk subgroups (diabetes, anterior MI, LV dysfunction)- Limitations of GISSI-3 in modern practice- Applying early ACE inhibitors clinically👉 Download the full clinical trial handout with a free membership at: https://www.thisiswhy.health/topics/gissi-3-trial-ace-inhibitors-after-mi-landmark-clinical👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources#GISSI3Trial #ACEinhibitorsMI #postMIcare #ventricularremodeling #Dr Bust👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#GISSI3Trial #ACEinhibitorsMI #postMIcare #ventricularremodeling #DrBustSpeaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content. 

Mean, median, mode, standard deviation, and standard error explained in the context of clinical research and data interpretation.In this This Is Why lecture, Dr. Busti walks through the core measures of central tendency and variability and shows how they relate to data type, study design, and proper interpretation.This is where many learners make mistakes—especially when interpreting skewed data, choosing between mean vs median, or understanding the difference between standard deviation and standard error.This episode builds directly on the Biostatistics Framework and helps you recognize when data may be misleading or incorrectly presented.Topics Covered:- Mean, median, and mode explained- Measures of variability and dispersion- Standard deviation vs standard error of the mean- How data type determines statistical description- Nominal, ordinal, and continuous data (applied concepts)- Skewed data (positive vs negative skew)- Relationship between mean, median, and mode- Interquartile range (IQR) explained- Identifying outliers in clinical data- 95% confidence interval (conceptual understanding)The goal = make medical education easy and clinically relevant.👉 Looking for Q-Banks to practice applying the concepts? We have Q-Banks at: https://www.highyieldmedreviews.com/ebm-biostatistics-literature-review-medicine📚 Need a structured curriculum for your university or residency program? We would love to discuss how we can partner with you: https://www.highyieldmedreviews.com/residency-training-programs-services-and-package👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#meanmedianmode #standarddeviation #standarderror #biostatisticsbasics #DrBustiSpeaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Amiodarone in cardiac arrest — Dr. Busti breaks down the ARREST trial and what it actually means for patient outcomes in this episode of This Is Why.When ventricular fibrillation persists after multiple shocks, what’s the next step? The ARREST trial gave us one of the first randomized answers—but understanding the why behind the results is what truly changes how you practice.Dr. Busti walks through the evidence behind amiodarone in shock-refractory VF/pulseless VT, highlighting what improved—and what didn’t. You’ll learn how to interpret short-term survival benefits, weigh adverse effects, and apply this data within modern ACLS algorithms.This is not just about memorizing steps—it’s about understanding the clinical impact so you can make better decisions under pressure.Topics Covered:- Why the ARREST trial was needed- Trial design and patient population- Survival to hospital admission vs meaningful outcomes- Amiodarone benefits and limitations- Adverse effects in cardiac arrest- ACLS guideline integration- Amiodarone vs lidocaine perspective- Clinical decision-making in refractory VF- Limitations of the ARREST trial- What actually improves survival in cardiac arrest👉 Download the full clinical trial handout and framework at: https://www.thisiswhy.health/topics/amiodarone-cardiac-arrest-trial-landmark-clinical👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.#amiodarone cardiac arrest #ARREST trial #ventricular fibrillation #ACLS algorithm #Dr BustiSpeaker:Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education.Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes.About This Channel:This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC).Disclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

What does “sternutate” actually mean, and why does medicine use complex terms for simple human experiences like sneezing? In this episode of This Is Why, Dr. Busti breaks down the medical term sternutate, its Latin origin, and how it connects to the physiology of sneezing as a protective reflex. This episode goes beyond memorization to focus on clinical reasoning—helping healthcare professionals understand how a common symptom like sneezing can point to underlying conditions such as allergic rhinitis, infections, or environmental triggers. If you want to better understand the “why” behind medical terminology and apply it to real patient care, this episode will help you think more clearly and clinically.👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 We'd love if you'd leave us a review on Apple Podcast or Spotify! It helps other clinicians like you find us. #sternutate #medicalterminology #sneezing #clinicalreasoning #drbustiSpeaker:Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education.Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes.About This Channel:This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC).Disclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Power analysis is essential for interpreting clinical research and determining whether a study can truly detect a meaningful difference.In this lecture on This Is Why, Dr. Busti will explain what statistical power really means, how it relates to beta and Type II error, and why sample size plays a critical role in identifying true differences in clinical studies. He walks through the conceptual meaning of power—not just the formula—and shows how clinicians and researchers should interpret study results when no difference is found.This lecture is part of the This Is Why (TIW) evidence-based medicine series, a connected playlist designed to build a deeper understanding of biostatistics and clinical reasoning. Be sure to explore the full series to strengthen your ability to critically evaluate medical literature.Topics Covered:- Definition of statistical power (1 − beta)- Type II error and its clinical meaning- Relationship between power and beta- Why power reflects the probability of detecting a true difference- Impact of sample size on study conclusions- Factors influencing power analysis- One-sided vs two-sided hypothesis testing- Study design considerations (crossover vs randomized trials)- Interpreting studies with no statistically significant difference- Clinical implications of underpowered studiesThe goal = make medical education easy and clinically relevant.👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#PowerAnalysis #TypeIIError #Biostatistics #EvidenceBasedMedicine #Dr BustiSpeaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Alpha value and Type I error are foundational concepts in biostatistics and clinical research interpretation.In this lecture on This Is Why, Dr. Busti will explain what alpha represents, how it is determined, and how clinicians should interpret it when evaluating medical literature. This session clarifies the relationship between alpha, Type I error, hypothesis testing, and study power, helping learners connect statistical theory to real clinical decision-making.This lecture is part of the broader This Is Why evidence-based medicine series, where each concept builds on previous topics to strengthen your ability to critically evaluate research.Be sure to explore the full playlist to connect concepts like hypothesis testing, power analysis, and statistical errors.Topics Covered:- Definition of alpha in clinical research- Alpha as probability of Type I error- Interpreting alpha in published studies- One-tailed vs two-tailed hypothesis testing- Relationship between alpha and study power- Type I error vs correct decision-making- Clinical implications of statistical error- Role of alpha in evidence-based medicineThe goal = make medical education easy and clinically relevant.👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#alpha value #type I error #biostatistics #clinical research #Dr BustiSpeaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Parametric vs Non-Parametric statistical tests are explained, and how they relate to data type, distribution, and study design.In this lecture on This Is Why, Dr. Busti brings the full biostatistics framework of the Statistical Analysis Plan (SAP) together—connecting data type, distribution, and study groups to the correct statistical analysis.Understanding when to use parametric vs. nonparametric tests is critical for interpreting clinical research and avoiding common mistakes when evaluating data in evidence-based medicine (EBM).This lecture reinforces how normal vs skewed data, outliers, and data classification influence statistical decision-making.Topics Covered:- Parametric vs nonparametric statistical tests- Normal distribution vs non-normal data- Role of data type in statistical analysis- Impact of outliers and skewed data- Nominal, ordinal, and continuous data review- How distribution affects test selection- Connecting data, groups, and statistical tests- Interpreting how data is presented in research- Clinical implications of incorrect statistical analysisThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/parametric-vs-nonparametric-statistical-tests-biostatistics👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#parametricvsnonparametric #biostatistics #statisticaltests #EBM #DrBustiSpeaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Independent vs paired study groups explained and how they determine the correct statistical test in clinical research.In this This Is Why lecture, Dr. Busti breaks down one of the most important steps in biostatistics—identifying the type of study groups and how that directly impacts statistical test selection.Understanding whether groups are independent or related is essential for interpreting clinical trials and avoiding common mistakes when reading research.This lecture builds on prior topics and moves you closer to confidently choosing the correct statistical analysis.Topics Covered:- Independent vs paired (related) study groups- How study design determines statistical testing- Randomized controlled trials and independent groups- Crossover and pre-post study designs- Matched and paired data concepts- Number of groups and its impact on analysis- Role of study groups in statistical decision-making- Connecting study design to hypothesis testing frameworkThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/independent-vs-paired-study-groups-biostatistics👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#independentvspaired #studygroups #biostatistics #clinicalresearch #Dr BustiSpeaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Parkinson disease medication discontinuation safety is the focus of this episode of This Is Why with Dr. Busti. In this board-style practice question, we work through a clinical scenario involving adverse effects, medication management, and the reasoning process needed to approach discontinuation decisions safely in practice and on exams.In this episode, Dr. Busti breaks down how to think through a medication safety question step by step, identify common board traps, and connect the pharmacology to real patient care.Topics Covered:- Parkinson disease medication management- Medication discontinuation safety- Adverse effects and treatment adjustment- Board-style pharmacology reasoning- How to analyze discontinuation questions- Common distractors in medication safety questions- Clinical thinking for neurologic drug therapy- Patient counseling during medication changesThe goal = make medical education easy and clinically relevant.👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#ParkinsonDisease #MedicationSafety #Pharmacology #ClinicalReasoning #DrBustiSpeaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Types of data for a study's endpoint are explained—nominal, ordinal, or continuous—and how each determines the appropriate statistical test in clinical research.In this lecture on This Is Why, Dr. Busti walks through one of the most critical steps in biostatistics: correctly identifying the type of data based on the study question.This is where many learners make mistakes—especially when distinguishing between ordinal vs continuous data, recognizing skewed data, or understanding when to use parametric vs non-parametric analysis.This lecture connects directly to prior topics on study groups and variability, bringing you closer to confidently choosing the correct statistical test.Topics Covered:- Nominal, ordinal, and continuous data explained- How the study question determines data type- Parametric vs non-parametric data concepts- Normal distribution vs skewed data- Relationship between mean, median, and mode- When continuous data should not be treated as parametric- Impact of outliers on data interpretation- Interpreting data for correct statistical test selection- How endpoints can change data classification (e.g., yes/no vs average)The goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/types-of-data-nominal-ordinal-continuous-biostatistics👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#typesofdata #nominalordinalcontinuous #biostatistics #clinicalresearch #Dr BustiSpeaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

How do you choose the right statistical test in clinical research?In this This Is Why (TIW) lecture, Dr. Busti introduces the biostatistics decision-making framework that connects hypothesis, study design, and data type to the correct statistical analysis.This is not a memorization lecture—it’s about understanding the structure behind statistical choices so you can evaluate research correctly as a clinician or researcher.This episode sets the foundation for the entire Biostatistics Framework series, where each concept builds step-by-step into practical application.If you’ve ever wondered why a specific statistical test was used in a paper—or whether it was the right one—this is where you start.Topics Covered:- Introduction to biostatistics in clinical research- How to choose the correct statistical test- Role of hypothesis in guiding analysis- Study design and its impact on statistical decisions- Understanding data types in research- Independent vs related groups- Internal validity and bias in clinical studies- Sample vs population inference- Null vs alternative hypothesis (conceptual review)- Overview of the statistical decision frameworkThe goal = make medical education easy and clinically relevant.👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#biostatistics #clinicalresearch #evidencebasedmedicine #epidemiology #DrBustiSpeaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

What is dyspnea, and why does it matter in clinical practice? In this episode of This Is Why, Dr. Busti breaks down the medical term dyspnea—commonly described as shortness of breath—and explain how healthcare professionals should think about it beyond simple definitions.Dyspnea should not be solely considered a diagnosis. It is a symptom that requires clinical reasoning. So the question becomes: what is driving the patient’s breathing discomfort? In this episode, Dr. Busti walks through the origin of the term, how it has been used historically, and how modern clinicians evaluate dyspnea across pulmonary, cardiac, and systemic causes.We also connect the concept to real-world scenarios, including examples from Top Gun and The Hunger Games, to help illustrate how breathlessness presents in both physiologic and pathologic contexts.If you’re a healthcare professional, student, or anyone looking to strengthen clinical thinking, this episode will help you understand not just what dyspnea means—but why it matters for patient care.Subscribe to This Is Why with Dr. Busti for more content focused on understanding the “why” behind medical terminology and clinical decision-making.👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resourcesChapter Table of Contents*** ADD TIMESTAMP & CHAPTER TITLES HERE ****👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#dyspnea #shortnessofbreath #clinicalreasoning #medicalterminology #drbustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Internal and external validity are foundational to interpreting clinical research and applying evidence in practice. In this This Is Why lecture, Dr. Busti explains how validity is established, what threatens it, and how clinicians should evaluate it during critical appraisal.This lecture is part of the This Is Why (TIW) evidence-based medicine series, helping clinicians connect study design to real-world decision-making.Topics Covered:- Internal validity vs external validity explained- Independent vs dependent variables- Causality in clinical research- Threats to internal validity (history, maturation, testing, instrumentation)- Statistical regression, selection, and mortality bias- Threats to external validity (testing, selection, setting)- Hawthorne effect and reactive behavior- Multiple-treatment interference- Applying evidence to patient care👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/internal-and-external-validity-research-design-methodology👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#internalvalidity #externalvalidity #biostatistics #studydesign #DrBustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Types of bias in research and their impact on results are critical to understanding study design, internal validity, and clinical decision-making. In this lecture on This Is Why, Dr. Busti walks through how bias is introduced, how it affects results, and how clinicians should interpret it.This lecture is part of the This Is Why evidence-based medicine (EBM) series, designed to help clinicians connect research methodology to real-world practice.Topics Covered:- Equation of error: truth, bias, and random error- Internal validity and critical appraisal- Selection bias and sampling bias- Confounding and lead-time bias- Recall bias and observer bias- Loss to follow-up and procedure bias- Differential vs non-differential misclassification- Study design hierarchy and risk of bias- Publication bias and clinical trial registries- Why bias control changes effect size👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/types-bias-clinical-research-design-methodology👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#bias in research #study design #internal validity #evidence based medicine #Dr BustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Picking the right benzodiazepine based on its metabolism is a critical concept for understanding medication safety, especially when considering hepatic function and drug accumulation. In this episode of This Is Why, Dr. Busti walks through a board-style practice question to break down how different metabolic pathways impact clinical decision-making.This case highlights how pharmacokinetics directly influences patient outcomes and why recognizing metabolism patterns is essential for safe prescribing.Topics Covered:- Benzodiazepine metabolism overview- Phase 1 vs Phase 2 hepatic drug metabolism- CYP450 oxidation and active metabolites- Glucuronidation and drug clearance- Pharmacokinetics in older adults- Drug accumulation and prolonged effects- Clinical decision-making in anxiolytic therapy- High-yield pharmacology concepts for board preparationThe goal = make medical education easy and clinically relevant.👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#benzodiazepinemetabolism #LOTdrugs #practicequestion #cyp450pharmacology #DrBustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

The ultimate guide to types of study designs used in clinical research is explained and made easy for clinicians and researchers. In this lecture on This Is Why, Dr. Busti walks through the major study designs used in medical research and explains how each design affects bias, causality, and the interpretation of clinical evidence. Dr. Busti also addresses the pros and cons of major study designs and when to use a particular study design to answer a particular clinical question. Understanding study design is essential for interpreting medical literature and assessing the internal and external validity of results, thereby informing the application of the information in clinical practice. Different designs—such as randomized controlled trials, cohort studies, case-control studies, and cross-sectional analyses—each have specific strengths, limitations, and risks of bias that influence how results should be applied in clinical practice.This lecture explains how study design fits into the broader clinical research process described by the NIH and how clinicians should evaluate studies when reading the medical literature.As part of the This Is Why (TIW) evidence-based medicine (EBM) series, this lecture focuses on the reasoning behind clinical evidence so clinicians can understand why certain study designs carry more evidentiary weight than others.Topics Covered:- Study design in clinical research- Descriptive vs analytic studies- Observational vs experimental research- Case-control studies- Cohort studies- Cross-sectional studies- Randomized controlled trials (RCTs)- Randomized crossover trials- Explanatory vs pragmatic clinical trials- Qualitative vs quantitative research- Study design hierarchy and risk of bias- Internal vs external validity- Confounders and bias in clinical trials- Clinical trial registration- CONSORT reporting guidelinesThis lecture is part of the This Is Why (TIW) evidence-based medicine (EBM) learning series with Dr. Busti. The series teaches clinicians how clinical studies are designed, how statistical results should be interpreted, and how research findings translate into real patient care decisions.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/types-of-study-designs-clinical-research-methodology-explained-ultimate-guide👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#StudyDesign #ClinicalResearch #EvidenceBasedMedicine #Biostatistics #Dr BustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Hypothesis testing is a core concept in biostatistics and evidence-based medicine. In this This Is Why lecture, Dr. Busti explains how hypotheses guide clinical research design and how clinicians interpret statistical results in medical literature.Understanding hypothesis testing helps clinicians determine whether study findings represent true differences or random chance. In this lecture, we break down null and alternative hypotheses, Type I and Type II errors, alpha and beta, statistical power, and one-tailed versus two-tailed analysis.Using the landmark HOPE Trial, Dr. Busti demonstrates how hypotheses are established a-priori and how proper study design strengthens internal validity and confidence in clinical trial results.This lecture is part of the This Is Why (TIW) Evidence-Based Medicine series with Dr. Busti, where clinicians learn how to interpret and apply clinical research in practice.Topics Covered:- What hypothesis testing means in clinical research- Null hypothesis vs alternative hypothesis- Type I error (alpha) and Type II error (beta)- Statistical power and sample size considerations- One-tailed vs two-tailed hypothesis testing- Why hypotheses must be defined a-priori- Interpreting p-values in clinical trials- Clinical example: the HOPE TrialThis video is part of the This Is Why Evidence-Based Medicine series. Explore the full playlist to continue learning how clinical research works and how to critically evaluate the medical literature.For additional learning resources, explore High-Yield Med Reviews. TIW members can find a member coupon in their TIW benefits section.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/hypothesis-testing-clinical-research👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.#Biostatistics #HypothesisTesting #EvidenceBasedMedicine #ClinicalResearch #DrBustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Clinical research design and the NIH clinical research process are explained for clinicians. In this This Is Why lecture, Dr. Busti introduces the foundations of clinical epidemiology, biostatistics, and clinical literature evaluation while walking through the NIH framework for how clinical research studies are designed and conducted.Understanding how clinical research is developed—from the original hypothesis to publication—is essential for clinicians who interpret medical literature and apply evidence to patient care. This lecture explains the structure behind clinical trials, research protocols, statistical analysis planning, and the ethical oversight required to conduct high-quality clinical studies.As part of the This Is Why series, this module focuses on the reasoning behind evidence-based medicine so clinicians can move beyond memorizing study results and instead understand how research actually works and how to evaluate the literature correctly.Throughout the TIW series, Dr. Busti connects clinical research design, biostatistics, diagnostic testing, and critical literature evaluation to real clinical decision-making.Topics Covered:- Clinical epidemiology vs biostatistics vs literature evaluation- Foundations of evidence-based medicine- The Five A's of evidence-based medicine- The EBM triad: evidence, clinician expertise, and patient values- NIH clinical research process- Study concept development and hypothesis formation- Protocol development and study design- Ethical oversight and institutional review boards- Study implementation and monitoring- Statistical analysis and interpretation- Communicating research results- Reporting standards, including CONSORT and PRISMA- Foundations for critical appraisal of clinical studiesThis lecture is part of the This Is Why (TIW) evidence-based medicine learning series with Dr. Busti. Each lecture builds on prior concepts to help clinicians develop a deeper understanding of clinical research and medical literature interpretation.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/nih-clinical-research-design-steps-process👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.#ClinicalResearchDesign #Biostatistics #EvidenceBasedMedicine #ClinicalEpidemiology #Dr BustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

CHA₂DS₂-VASc score atrial fibrillation is a critical concept for determining when anticoagulation is recommended. In this episode of This Is Why with Dr. Busti, we break down a board-style clinical question to explain when anticoagulation should NOT be started in atrial fibrillation.Understanding stroke risk stratification is essential for USMLE, NAPLEX, NP, PA, and medical board exams. This episode walks step-by-step through the reasoning behind anticoagulation decisions using the CHA₂DS₂-VASc scoring system.Topics Covered- CHA₂DS₂-VASc score interpretation- Atrial fibrillation stroke prevention- When anticoagulation is not recommended- AF anticoagulant dosing traps for board exams- Warfarin vs DOAC dosing in AF- Board exam test-taking strategies for AF management The goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/cha2ds2-vasc-score-atrial-fibrillation-board-question👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#afib #atrialfibrillation #cha2ds2vasc #anticoagulation #drbustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

What is proctalgia fugax, and why does this term matter in real clinical practice? In this episode of This Is Why, Dr. Busti breaks down the meaning of proctalgia fugax, its etymology, how it has been understood historically, and how healthcare professionals should use the term today. This lesson focuses on concept-based learning, helping clinicians connect the terminology to differential diagnosis, disorders of gut-brain interaction, and the practical question of whether brief anorectal pain fits proctalgia fugax or points to something else. If you want to understand the “why” behind the words we use in medicine, this episode will help you think more clearly about anorectal pain, diagnosis of exclusion, and patient-centered clinical reasoning.The goal = make medical education easy and clinically relevant.👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#proctalgiafugax #medicalterminology #anorectalpain #clinicalreasoning #drbustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Short-acting muscarinic antagonists (SAMAs) are a core bronchodilator drug class you’ll see constantly in COPD care. In this lecture from This is Why, Dr. Busti will learn about short-acting muscarinic antagonists (SAMAs) are a core bronchodilator drug class you’ll see constantly in COPD care—and on exams like the NCLEX. In this lecture, you’ll learn exactly how SAMAs work, when to use them, and what safety pearls can help you avoid common clinical pitfalls in COPD.You’ll learn how to:Mechanism of action: muscarinic (M3) blockade → decreased bronchoconstrictionKey drug: ipratropium (Atrovent)Common combinations: ipratropium/albuterol (DuoNeb, Combivent)Clinical uses: COPD maintenance/symptom relief, COPD exacerbation support, select asthma situations (often as add-on therapy in acute care)Routes & devices: MDI vs nebulized treatments, dosing frequency, and practical inhaler/neb pearlsAdverse effects & warnings: dry mouth, cough, urinary retention (BPH), blurry vision/precipitating angle-closure symptoms if sprayed into eyes, and other anticholinergic considerationsHigh-yield comparisons: SAMA vs LAMA (where tiotropium and other long-acting agents fit)The goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/sama-short-acting-muscarinic-antagonist-ipratropium-bronchodilatorGet more with a free membership at https://www.thisiswhy.health/Access free downloads from our videos Access deep dive content from Dr. BustiOrganize content via playlists & collectionsJoin live Q&AReceive member newslettersCoupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!Disclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lecture from This is Why, Dr. Busti will explain the COPD maintenance inhalers you’ll actually see in practice. In this pharmacology review, we break down LAMA (long-acting muscarinic antagonist) bronchodilators—one of the most important bronchodilator classes for COPD treatment—so you can confidently understand the drugs, the mechanism, and the real-world clinical use.You’ll learn how to:What LAMA / antimuscarinic bronchodilators are and how they workWhere LAMA inhalers fit in COPD therapy and long-term symptom controlKey differences and practical pearls for common COPD inhalersHigh-yield side effects, contraindications, and patient counseling pointsHow to recognize and avoid common med errors and confusion with inhaler names/classesDrugs covered:Tiotropium (Spiriva)Umeclidinium (Incruse Ellipta)Aclidinium (Tudorza Pressair)Glycopyrrolate (COPD maintenance formulations)The goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/lama-bronchodilators-copd-tiopotropium-umeclidinium-pharmacologyGet more with a free membership at https://www.thisiswhy.health/Access free downloads from our videos Access deep dive content from Dr. BustiOrganize content via playlists & collectionsJoin live Q&AReceive member newslettersCoupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!Disclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lecture from This is Why, Dr. Busti will break down SABA (Short-Acting Beta Agonist) bronchodilators, like albuterol, for the acute management of asthma symptoms and COPD flare-ups.You’ll learn how to:- What SABAs are and when they’re used (rescue vs controller)- Beta-2 agonist mechanism of action (bronchodilation and smooth muscle effects)- How fast albuterol works, typical duration, and why it’s “short-acting”- Core therapeutic uses in asthma and COPD- How SABAs fit into treatment plans (including “as needed” use)- Common adverse effects: tachycardia, tremor, palpitations, and more- Key patient counseling: inhaler technique and when to seek urgent careDrugs discussed:- Albuterol (rescue inhaler; MDI and nebulizer)- Levalbuterol (alternative SABA)The goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/saba-short-acting-beta-agonists-albuterol-rescue-inhaler-asthma-copdGet more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#SABA #albuterol #asthma #COPD #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lecture from This is Why, Dr. Busti will explain how Long-Acting Beta Agonists (LABAs) work, where they fit in therapy for the management of asthma and COPD.You’ll learn how to:- Mechanism of action: beta-2 receptor activation → bronchodilation (airway smooth muscle relaxation)- Clinical use: LABAs in COPD maintenance vs asthma (must be combined with ICS)- Onset/duration differences and practical inhaler considerations- Adverse effects & warnings: tachycardia, tremor, hypokalemia, paradoxical bronchospasm, and key safety concepts- Therapeutic combos: ICS/LABA combination inhalers and where they fit (including common guideline concepts)LABA drugs discussed for SEO/review:- Salmeterol- Formoterol- Vilanterol- Olodaterol- IndacaterolThe goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/laba-long-acting-beta-agonists-asthma-copd-bronchodilators-pharmacologyGet more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#LABA #LongActingBetaAgonist #Asthma #Bronchodilators #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lecture from This is Why, Dr. Busti will break down pioglitazone and the thiazolidinediones (TZDs) so you can confidently explain the mechanism, clinical use, side effects, and key contraindications for type 2 diabetes (T2DM).You’ll learn how to:- TZDs (pioglitazone): where they fit in type 2 diabetes (T2DM) therapy- Mechanism of action: PPAR-γ agonist → increased insulin sensitivity (muscle/adipose) and improved glucose utilization- Expected impact on A1C reduction and how long these drugs take to show benefit- Practical comparisons: pioglitazone vs rosiglitazoneSide effects & safety (high yield)- Weight gain and edema / fluid retention- Heart failure risk (when to avoid TZDs)- Fracture risk with TZDsDrugs covered for SEO / review- Pioglitazone (primary focus)- Thiazolidinediones / TZDs (drug class)- Rosiglitazone (comparison)The goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/tzd-thiazolidinediones-pioglitazone-type-2-diabetes-pharmacology-reviewGet more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#pioglitazone #thiazolidinediones #tzd #type2diabetes #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Dr. Busti covers one of the most-tested Type 2 diabetes drug classes—sulfonylureas. If you’ve ever mixed up glyburide vs glipizide, worried about hypoglycemia, or wanted a clear “when do I pick this?” framework, this drug class review is for you. In this lecture from This is Why, Dr. Busti will break down Sulfonylureas (Glyburide, Glipizide) step-by-step so you can confidently in the context of treating type 2 diabetes (T2DM).You’ll learn how to:- Mechanism of action: how sulfonylureas increase insulin release- Clinical use: where sulfonylureas still fit in modern Type 2 diabetes management- Drug comparisons: key differences between glyburide, glipizide, and glimepiride- Adverse effects: why hypoglycemia risk matters, plus weight gain and common pitfalls- Safety & patient selection: older adults, renal impairment, missed meals, and other high-risk scenariosKey drugs covered:- Glipizide- Glyburide - Glimepiride- (Plus core concepts of oral hypoglycemics, insulin secretagogues, and antidiabetic drugs)The goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/sulfonylureas-glipizide-glyburide-type-2-diabetes-pharmacologyGet more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#sulfonylureas #type2diabetes #glipizide #glyburide #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

SGLT2 inhibitors (bexagliflozin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) don’t just lower glucose and A1C, but these meds have become relevant in cardiovascular disease and chronic kidney disease in the right patients also with type 2 diabetes (T2DM). In this lecture from This is Why, Dr. Busti will make the SGLT2 inhibitors make sense as they provide cardiorenal protection above their improvements in A1C.You’ll learn how to:- Mechanism of action (MOA): how SGLT2 blockade drives glucosuria, modest A1c reduction, weight loss, and BP lowering- Clinical use: where SGLT2 inhibitors fit for type 2 diabetes, plus major outcomes in heart failure and chronic kidney disease (CKD) (cardiorenal protection is a key reason they’re prioritized in modern guidelines)- Key drugs (for exams + real-world practice): Empagliflozin (Jardiance), Dapagliflozin (Farxiga), Canagliflozin (Invokana), Ertugliflozin (Steglatro), and Bexagliflozin (Brenzavvy)- Adverse effects & safety pearls: genital mycotic infections, volume depletion/hypotension, AKI considerations, and the “don’t-miss” rare events like euglycemic DKA (plus how to recognize it)The goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/sglt2-inhibitors-canagliflozin-dapagliflozin-empagliflozin-diabetes-pharmacology-reviewGet more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#sglt2inhibitors #empagliflozin #type2diabetes #diabetespharmacology #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Meglitinides (Nateglinide & Repaglinide) can feel like the “forgotten” oral diabetes drugs—but they show up on exams, in real-world medication histories, and in questions about postprandial glucose control and hypoglycemia and weight gain risk. In this lecture from This is Why, Dr. Busti will explain the meglitinides in a clear, clinically relevant way so you can recognize them quickly and use the concepts confidently in the context of Type 2 diabetes (T2DM).You’ll learn how to:- Meglitinides overview: where they fit in type 2 diabetes (T2DM) therapy- Drug names you must know: repaglinide and nateglinide- Mechanism of action: how these insulin secretagogues stimulate insulin release (the KATP channel connection)- Onset/duration & dosing concept: why they’re considered short-acting / prandial glucose agents- Therapeutic application: targeting postprandial hyperglycemia and when they may (or may not) be chosen- Adverse effects & safety: hypoglycemia, weight considerations, and key patient counseling pointsThe goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/meglitinides-repaglinide-nateglinide-diabetes-pharmacology-reviewGet more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#meglitinides #repaglinide #nateglinide #type2diabetes #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Insulin doesn’t have to be confusing when learning how to treat Type 1 and Type 2 diabetes mellitus. In this lecture from This is Why, Dr. Busti will explain how to quickly recognize insulin types, predict onset/peak/duration, and apply basal–bolus dosing concepts to real-world Type 1 and Type 2 diabetes care.You’ll learn how to:- How to identify rapid-, short-, intermediate-, and long-acting insulin for Diabetes- The difference between basal insulin vs bolus (mealtime) insulin- How basal–bolus regimens work (plus common pitfalls)- Practical tips for insulin administration, timing with meals, and avoiding errors- High-yield clinical points you’re likely to see in courses and on examsInsulins covered (for memorization + exam success):- Rapid-acting: insulin lispro, aspart, glulisine- Short-acting: regular insulin- Intermediate-acting: NPH insulin- Long-acting / basal: insulin glargine, detemir, degludec- Premixed options: 70/30 mixes (NPH/regular and related premixed products)The goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/insulin-types-diabetes-pharmacology-reviewGet more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#insulin #diabetes #insulintypes #diabetespharmacology #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Understand the GLP-1 receptor agonists—and why agents like semaglutide (Ozempic/Wegovy/Rybelsus), liraglutide, dulaglutide, and exenatide have become one of the most talked-about type 2 diabetes medications in modern practice. In this lecture from This is Why, Dr. Busti will break GLP-1s down in a clear, clinically relevant way so you can confidently explain how they work, when to use them, and what to watch for clinically when managing patients with type 2 diabetes and/or obesity.You’ll learn how to:- Mechanism of action: incretin mimetic effects (GLP-1) and what that means for glucose control- Therapeutic use: where GLP-1 agonists fit in type 2 diabetes (T2DM) treatment strategies- Key agents: semaglutide, plus comparisons to liraglutide, dulaglutide, and exenatide- Benefits & counseling pearls: weight effects, dosing basics, and practical patient education- Adverse effects & precautions: the high-yield safety points clinicians get tested on (and seen in clinical practice)The goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/glp-1-receptor-agonists-semaglutide-dulaglutide-liraglutide-diabetes-pharmacology-reviewGet more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#glp1receptoragonist #semaglutide #type2diabetes #diabetesmedications #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Tirzepatide (Mounjaro/Zepbound)—the dual incretin GIP/GLP-1 agonist—is a beneficial treatment of type 2 diabetes and/or obesity.  In this lecture from This is Why, Dr. Busti will break down how tirzepatide works (MOA), why combining GIP + GLP-1 improves A1C reduction and supports weight loss, and where it fits in the treatment of type 2 diabetes. You’ll also get the high-yield points you need for exams and the bedside: tirzepatide dosing basics, common adverse effects, contraindications/precautions, and practical tips for patient counseling (nausea, GI effects, injection technique, and expectations).You’ll learn how to:- Tirzepatide overview: Mounjaro vs Zepbound- GIP/GLP-1 agonist mechanism (dual incretin)- Clinical use in type 2 diabetes- A1C lowering + weight loss effects- Adverse effects, warnings, and counseling pearlsThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/tirzepatide-mounjaro-zepbound-gip-glp1-agonist-type-2-diabetes-pharmacology👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#tirzepatide #mounjaro #gipglp1 #type2diabetes #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lecture from This is Why, Dr. Busti will learn about the application of DPP-4 inhibitors in the management of type 2 diabetes mellitus (T2DM). The DPP-4 inhibitors (e.g., sitagliptin, linagliptin, saxagliptin) have an impact of incretins (GIP, GLP-1) which have continued to evolve in other treatment options.You’ll learn how to:- Mechanism of action: DPP-4 inhibition and impact on incretins (GLP-1/GIP) - Key drugs: Sitagliptin, linagliptin, saxagliptin- Clinical role: where DPP-4 inhibitors fit in type 2 diabetes treatment, including add-on therapy- Adverse effects & safety pearls: the side effects and warnings you need to know for exams and practiceThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/dpp-4-inhibitors-sitagliptin-type-2-diabetes-pharmacology👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#dpp4inhibitors #type2diabetes #sitagliptin #diabetespharmacology #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Metformin is a first-line oral medication for type 2 diabetes.  In this lecture from This is Why, Dr. Busti will explain how metformin works to lower the A1c and help patients with type 2 diabetes get to their A1C goals. You’ll learn how to:- Metformin mechanism of action (MOA): how biguanides lower glucose and improve insulin resistance- Where metformin fits in type 2 diabetes therapy (first-line option and combination use)- Key clinical benefits (A1C lowering, weight neutrality/possible weight loss)- Dosing basics and titration strategies (including extended-release considerations)- High-yield adverse effects: GI effects, vitamin B12 concerns, and the real story on lactic acidosis- Contraindications and precautions (renal function, acute illness, contrast studies, alcohol use)- Monitoring and patient counseling points you should know for practice and examThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/metformin-biguanide-type-2-diabetes-pharmacology👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#metformin #type2diabetes #diabetespharmacology #biguanide #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Amylin Analogs (Pramlintide) for Diabetes: Pharmacology Made Easy.  In this lecture from This is Why, Dr. Busti will explain how pramlintide (Symlin/SymlinPen) works and when it’s used as an adjunct to insulin for type 1 diabetes (and select type 2 diabetes cases). In this diabetes pharmacology review, I break down the mechanism of action of an amylin analog, why it helps postprandial glucose control, and the key clinical pearls you need for exams and practice.You’ll learn how to:- What amylin does physiologically and how pramlintide mimics it- How pramlintide lowers post-meal blood glucose (slows gastric emptying, suppresses glucagon, increases satiety)- How to use pramlintide with mealtime insulin (timing + dose adjustment concepts)- Adverse effects & safety: nausea, hypoglycemia risk, and major counseling pointsThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/amylin-analogs-pramlintide-diabetes-pharmacology👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#pramlintide #amylinanalog #diabetespharmacology #type1diabetes #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lecture from This is Why, Dr. Busti will teach you about Alpha-Glucosidase Inhibitors for Diabetes — the pharmacology made easy breakdown of acarbose and miglitol for type 2 diabetes.You’ll learn how to:- Explain how alpha-glucosidase inhibitors reduce postprandial hyperglycemia- Identify where these drugs work (GI tract) and why they don’t cause hypoglycemia by themselves- Compare acarbose vs miglitol (what’s similar, what’s different)- Recognize common GI adverse effects (e.g., flatulence, diarrhea, abdominal discomfort)- Know when they are (and are not) used in type 2 diabetes medications- Apply patient counseling: timing with meals + what to do if hypoglycemia occurs on combination therapyThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/alpha-glucosidase-inhibitors-acarbose-miglitol-type-2-diabetes-pharmacology👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#alphaglucosidaseinhibitors #acarbose #miglitol #type2diabetespharmacology #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Statins (HMG-CoA Reductase Inhibitors) are the foundation of LDL lowering and ASCVD prevention. In this lecture from This is Why, Dr. Busti will make statin pharmacology easy to understand, but also clinically relevant in the proper context of the evidence. The use of HMG CoA reductase inhibitors: atorvastatin, rosuvastatin, simvastatin, pitavastatin, and pravastatin are drugs in this drug class that Dr. Busti will review. You’ll learn how to:MOA: How HMG-CoA reductase inhibitors reduce hepatic cholesterol synthesis and increase LDL clearanceClinical uses: Hyperlipidemia treatment, primary prevention, and secondary prevention for ASCVDHigh-yield statins: Atorvastatin, rosuvastatin, simvastatin, pravastatin (and how to think about intensity)Adverse effects: Statin myopathy, muscle pain/weakness, and rare rhabdomyolysisKey interactions: CYP3A4 interactions (especially with certain statins) and what to watch for clinicallyPearls for exams: How to connect lipid lowering drugs to patient cases and test questionsThe goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/statins-hmg-coa-reductase-inhibitors-ldl-loweringGet more with a free membership at https://www.thisiswhy.health/Access free downloads from our videos Access deep dive content from Dr. BustiOrganize content via playlists & collectionsJoin live Q&AReceive member newslettersCoupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#statins #hmgcoareductaseinhibitors #ldllowering #lipidloweringdrugs #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Omega-3 fatty acids made easy: learn EPA vs DHA, how fish oil works, and when to use icosapent ethyl (Vascepa) in real clinical practice. In this lecture from This is Why, Dr. Busti connects PUFAs (polyunsaturated fatty acids) to outcomes, focusing on triglyceride lowering, cardiovascular risk reduction, and the key differences between OTC fish oil supplements and prescription EPA.You’ll learn how to:What omega-3 fatty acids (EPA & DHA) are and how they workFish oil (EPA vs DHA): what matters clinically (and what doesn’t)How omega-3s affect triglycerides and hypertriglyceridemiaIcosapent ethyl vs “fish oil”: dosing, indications, and counselingThe goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/omega-3-fatty-acids-epa-vs-dha-fish-oil-icosapent-ethylGet more with a free membership at https://www.thisiswhy.health/Access free downloads from our videos Access deep dive content from Dr. BustiOrganize content via playlists & collectionsJoin live Q&AReceive member newslettersCoupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#omega3fattyacids #fishoil #icosapentethyl #EPADHA #bustiDisclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Learn fibrates (fibric acid derivatives)—fenofibrate and gemfibrozil—common triglyceride-lowering drugs for hypertriglyceridemia. In this lecture from This is Why, Dr. Busti will break down how fibrates (fenofibrate and gemfibrozil) work, when to use them, and the safety pearls you need for the patient with high triglycerides, which can lead to pancreatitis.You’ll learn how to:- Mechanism: PPAR-α activation → ↓ triglycerides (TG), ↓ VLDL, ↑ HDL- Fenofibrate vs gemfibrozil: key differences that matter for practice questions- Indications: managing high triglycerides (including reducing pancreatitis risk in severe TG)- Adverse effects & monitoring: myopathy risk, LFTs, gallstones, and what to watch for- Drug interactions: especially with statins (testable!)The goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/fibrates-fenofibrate-gemfibrozil-hypertriglyceridemia-triglycerides-pharmacology👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#fibrates #fenofibrate #gemfibrozil #hypertriglyceridemia #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lecture from This is Why, Dr. Busti will break down Ezetimibe (Zetia)—the classic cholesterol absorption inhibitor—and make the pharmacology easy, high-yield, and clinically relevant. You’ll learn how ezetimibe lowers LDL-C, where it fits in dyslipidemia/hyperlipidemia therapy, and how it’s commonly used as add-on therapy to statins.You’ll learn how to:- Mechanism of action: how the cholesterol absorption inhibitor, ezetimibe, works to lower LDL cholesterol- Clinical use: when to use ezetimibe for LDL-C lowering (including statin add-on therapy)- Key benefits & limitations: what ezetimibe does well—and what it does not do- Adverse effects & counseling pearls: what to watch for in practiceThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/ezetimibe-zetia-cholesterol-absorption-inhibitor-ldl-pharmacology👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#ezetimibe #cholesterolabsorptioninhibitor #zetia #ldlcholesterollowering #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

ATP Citrate Lyase (ACL) Inhibitors made simple.  In this lecture from This is Why, Dr. Busti will provide you with a review of Bempedoic Acid (Nexletol), and you’ll learn how this lipid-lowering drug works, when to use it (including statin intolerance), and the key clinical pearls you need for exams and practice.You’ll learn how to:- What ATP citrate lyase inhibitors are and where they work in cholesterol synthesis- Bempedoic acid mechanism of action + why it’s different from statins- Effects on LDL cholesterol (LDL lowering drugs overview)- Indications: hyperlipidemia, dyslipidemia, ASCVD risk reduction, statin-intolerant patients- High-yield adverse effects, contraindications, and monitoring- Drug interactions and counseling points you’ll actually useThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/bempedoic-acid-nexletol-acl-inhibitor-review👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#lipidloweringdrugs LDLdrugspharmacology #BempedoicAcid #nexletol #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Dive into the coagulation cascade with this clear, clinically focused review! In this lecture from This is Why, Dr. Busti breaks down the coagulation cascade in a clear, clinically relevant way—perfect for healthcare professionals preparing for exams or patient care. Dr. Busti specifically covers the basics of hemostasis, the intrinsic and extrinsic pathways, clotting factors, vitamin K-dependent factors, thrombin functions, and how the cascade leads to thrombus formation (including key differences between venous and arterial thrombi). Learn "why" understanding normal physiology is essential for recognizing pathology and choosing the right interventions to prevent bleeding or thrombosis.Key topics include:- Normal clotting factor synthesis & activation- Role of vitamin K and the coagulation cascade- Thrombin's multiple functions in clot formation, stabilization, and fibrinolysis- Clinical relevance: What happens when the balance is disrupted?Whether you're studying or simply want to understand the "why" behind anticoagulation and hemostasis management, this physiology review makes complex concepts easy and applicable.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/coagulation-cascade-thrombosis-physiology-made-easyGet more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#CoagulationCascade #Hemostasis #BloodClottingCascade #PhysiologyMadeEasy #drbustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Platelet aggregation is a core step in hemostasis—and when it’s dysregulated, it drives thrombosis. In this lecture from This is Why, Dr. Busti will break down platelet physiology in a clear, clinically relevant way so you can understand how platelets form a primary hemostatic plug, how a thrombus develops, and why this process matters in real patient care.You’ll learn how to:- How platelet adhesion starts (the role of von Willebrand factor (vWF) and GPIb)- How platelet activation amplifies the response (ADP and thromboxane A2 / TXA2)- How platelet aggregation occurs (GPIIb/IIIa binding fibrinogen)- The key endogenous “brakes” that limit clot growth (nitric oxide and prostacyclin / PGI2)- How clinicians think about platelet function testing and antiplatelet drugs in practiceThe goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/platelet-aggregation-thrombosis-clinical-essentialsGet more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#PlateletAggregation #Thrombosis #Hemostasis #PlateletPhysiology #drbustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lesson on glycoprotein (GP) IIb/IIIa (GPIIb/IIIa) inhibitors, you’ll learn the high-yield, test-relevant concepts behind the adjunct antiplatelet drug therapy used in the acute management of patients experiencing an acute myocardial infarction (AMI; NSTEMI, STEMI) and undergoing PCI or coronary stent placement. In this lecture from This is Why, Dr. Busti will break down how platelet aggregation inhibitors work, when they’re used clinically, and the key differences between tirofiban and eptifibatide —so you can apply the “why” behind therapy (not just memorize drug names).You’ll learn how to:- The GPIIb/IIIa receptor and how blocking it reduces platelet activation- Where GPIIb/IIIa inhibitors fit in clinical practice- High-yield uses: acute coronary syndrome (ACS) and PCI/stents- Major adverse effects (including bleeding) and top safety pearlsThe goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/gpiibiiia-inhibitors-tirofiban-eptifibatide-antiplatelet-pharmacology-reviewGet more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#gpiibiiiainhibitors #tirofiban #antiplateletpharmacology #eptifibatide #drbustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lesson on P2Y12 inhibitors (ADP inhibitors), you’ll learn the high-yield, test-relevant concepts behind the most common antiplatelet drugs used in cardiovascular care. In this lecture from This is Why, Dr. Busti will break down how platelet aggregation inhibitors work, when they’re used clinically, and the key differences between clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta), and cangrelor (Kengreal)—so you can apply the “why” behind therapy (not just memorize drug names).You’ll learn how to:- The P2Y12 (ADP) receptor and how blocking it reduces platelet activation- Where P2Y12 inhibitors fit in dual antiplatelet therapy (DAPT)- High-yield uses: acute coronary syndrome (ACS), PCI/stents, and secondary prevention- Major adverse effects (including bleeding) and top safety pearls- The exam-favorite comparisons: prodrug activation, onset/offset, reversibility, and IV vs PO optionsThe goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/p2y12-adp-inhibitors-antiplatelet-pharmacology-reviewGet more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#p2y12inhibitors #clopidogrel #antiplateletpharmacology #ticagrelor #drbustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Master Aspirin (ASA) fast with this Antiplatelet Pharmacology Made Easy & Relevant lecture. In this lecture from This is Why, Dr. Busti will make sure you learn how acetylsalicylic acid works as an antiplatelet drug, including COX-1 inhibition, decreased thromboxane A2 (TXA2), and reduced platelet aggregation—plus the key clinical takeaways for MI prevention, stroke prevention, and secondary prevention.You’ll learn how to:- Aspirin mechanism of action (COX inhibitor → ↓ TXA2 → ↓ platelet aggregation)- Why aspirin is different from other NSAIDs in antiplatelet therapy- High-yield uses in cardiovascular pharmacology (MI/stroke prevention)- Side effects, contraindications, and safety pearls you need for examsThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/aspirin-asa-salicylic-acid-antiplatelet-pharmacology-review👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#aspirin #asa #aspirinpharmacology #antiplateletdrugspharmacology #drbustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lecture from This is Why, Dr. Busti will break down Heparin (UFH) and Low-Molecular-Weight Heparins (LMWHs), such as enoxaparin (Lovenox) and dalteparin (Fragmin), with a clear, clinically relevant approach. If you’re studying anticoagulation or need a fast refresher on anticoagulants, this video is for you.In this lesson, you’ll learn:- Heparin mechanism of action (UFH vs LMWH) + how they work in the clotting cascade- Monitoring & labs: aPTT/PTT for UFH, anti–Factor Xa concepts for LMWH- Dosing/administration pearls (IV vs SQ, onset/offset, bridging basics)- Adverse effects & safety: bleeding, HIT (heparin-induced thrombocytopenia), contraindications- Clinical comparisons: heparin vs enoxaparin, when each is commonly usedThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/heparins-ufh-lmwh-anticoagulants-pharmacology-review👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#UnfractionatedHeparin #LowMolecularWeightHeparin #Enoxaparin #Anticoagulation #drbustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition, and never delay care because of educational content.

Warfarin (Vitamin K Antagonist; VKA) doesn’t have to be confusing. In this lecture from This is Why, Dr. Busti will explain warfarin's (Coumadin) pharmacology in a simple, clinically relevant way. It is perfect for anyone reviewing anticoagulation.You’ll learn how to:- Mechanism of action: how warfarin works as a vitamin K antagonist (VKA) (VKOR inhibition)- What PT/INR measures and why INR monitoring matters- How to start warfarin dosing (and what affects dose response)- Bridging with heparin/LMWH (warfarin bridge / heparin bridge) and when it’s needed- High-yield warfarin interactions (CYP2C9 inhibitors/inducers) + vitamin K foods- Warfarin reversal basics (including vitamin K reversal)The goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/warfarin-vka-coumadin-anticoagulants-pharmacology-review👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#WarfarinPharmacology #VitaminKAntagonist #WarfarinDosing #WarfarinInteractions #drbustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Factor Xa inhibitors (DOACs) made easy—fast, clear, and clinically relevant. In this lecture from This is Why, Dr. Busti will break down direct oral anticoagulants (DOACs) and how Factor Xa inhibitors work, with relevance.You’ll learn how to:- What Factor Xa inhibitors do (mechanism of action)- Key drugs: Apixaban (Eliquis), Rivaroxaban (Xarelto), Edoxaban (Savaysa)- Common indications: Afib stroke prevention, DVT/PE treatment- Major adverse effects and safety: bleeding risk, interactions, and monitoring pearls- Reversal overview: What to know + when it mattersThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/doac-factor-xa-inhibitors-anticoagulants-pharmacology-review👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#FactorXaInhibitors #DOACs #Anticoagulation #Apixaban #drbustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Direct Thrombin Inhibitors (DTIs) made simple and clinically relevant! In this lecture from This is Why, Dr. Busti will help you master direct thrombin (Factor IIa) inhibitors—including the oral DTI dabigatran (Pradaxa) and key parenteral DTIs like bivalirudin (and where argatroban fits clinically, especially in the acute care setting)You’ll learn how to:- Where direct thrombin inhibitors work in the coagulation cascade- How dabigatran works (mechanism of action), major indications, and high-yield adverse effects- What to monitor, common drug interactions, and who is at higher bleeding risk- Dabigatran reversal with idarucizumab (Praxbind)- PCI anticoagulation and how DTIs show up in clinical practice (including HIT treatment concepts)The goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/direct-thrombin-inhibitors-DTI-doac-anticoagulants-pharmacology-review👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#directthrombinInhibitors #DTIpharmacology #DabigatranPharmacology #Anticoagulation #drbustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.